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ABSTRACT
Background The genetic aetiology of
neurodevelopmental defects is extremely diverse, and the
lack of distinctive phenotypic features means that genetic
criteria are often required for accurate diagnostic
classiﬁcation. We aimed to identify the causative genetic
lesions in two families in which eight affected individuals
displayed variable learning disability, spasticity and
abnormal gait.
Methods Autosomal recessive inheritance was
suggested by consanguinity in one family and by sibling
recurrences with normal parents in the second.
Autozygosity mapping and exome sequencing,
respectively, were used to identify the causative gene.
Results In both families, biallelic loss-of-function
mutations in HACE1 were identiﬁed. HACE1 is an E3
ubiquitin ligase that regulates the activity of cellular
GTPases, including Rac1 and members of the Rab
family. In the consanguineous family, a homozygous
mutation p.R219* predicted a truncated protein entirely
lacking its catalytic domain. In the other family,
compound heterozygosity for nonsense mutation p.
R748* and a 20-nt insertion interrupting the catalytic
homologous to the E6-AP carboxyl terminus (HECT)
domain was present; western blot analysis of patient
cells revealed an absence of detectable HACE1 protein.
Conclusion HACE1 mutations underlie a new
autosomal recessive neurodevelopmental disorder.
Previous studies have implicated HACE1 as a tumour
suppressor gene; however, since cancer predisposition
was not observed either in homozygous or heterozygous
mutation carriers, this concept may require re-evaluation.
INTRODUCTION
Intellectual disability (ID) is characterised by the
impairment of general mental abilities associated
with defects in adaptive function. Many patients
with ID exhibit additional clinical features or symp-
toms, such as motor abnormalities or epilepsy,
reﬂecting variable developmental abnormalities of
the brain. ID affects ∼2%–3% of the general popu-
lation and, with recent advancements in genetic
technology, there has been an increasing emphasis
on identifying the genetic basis for neurodevelop-
mental disorders. The wide phenotypic spectrum
of neurodevelopmental disorders reﬂects a huge
diversity of underlying genetic and epigenetic path-
ologies.1 For single-gene inherited disorders, the
pace of gene discovery has been greatly accelerated
through the availability of whole exome sequen-
cing. However, many neurodevelopmental disor-
ders do not display phenotypic characteristics that
are sufﬁciently distinctive to allow cohort ascertain-
ment on a prospective basis. This has led to a
variety of investigative approaches. It may be pos-
sible to map and identify causative genes within
single large multiplex families, particularly if paren-
tal consanguinity can be exploited.2 Alternatively,
heterogeneous cohorts of sporadic cases may be
subjected to large-scale sequencing and post-hoc
genetic classiﬁcation, with varying degrees of
success.3 In general, the pathogenicity of mutations
identiﬁed within single families is likely to require
additional support from unrelated cases or from
other experimental sources. Searchable collabor-
ation forums such as GeneMatcher4 may prove to
be increasingly valuable in this respect.
Here, we describe two families in which eight indi-
viduals displayed a variable neurodevelopmental
phenotype with ID, spasticity and abnormal gait.
Because of the consanguinity in one family and sibling
recurrences in the other, an autosomal recessive inher-
itance was suspected. Autozygosity mapping followed
by candidate gene sequencing and exome sequencing
were used to identify loss of function mutations in
HACE1, which encodes a HECT domain- and
ankyrin repeat-containing E3 ubiquitin protein ligase.
HACE1 is believed to regulate the activity of a number
of small GTPases, and previous genetic studies have
mostly implicated it as a tumour suppressor.
METHODS
Patients
A consultant clinical geneticist evaluated all patients
at least once and comprehensive clinical history,
examination and review of medical notes were per-
formed and documented. Longitudinal information
over a number of years was available for most of
the individuals. DNA samples were obtained after
written informed consent from subjects or their
parents, according to a protocol approved by the
Research Ethics Committees in Leeds (East) (refer-
ence 07/H1306/113) and the University of Lübeck.
Gene identiﬁcation
Genotyping of family A (affected individuals and
parents, see ﬁgure 1A) was initially performed
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using the Affymetrix GeneChip Mapping 10K array; patients 1–
5 were also later genotyped using the genome-wide human SNP
6.0 array, permitting ﬁner resolution (see online supplementary
ﬁgure S1). Data were analysed for autozygosity using
AutoSNPa;5 for mapping purposes, only patients 1–4 were
grouped as affected, because of the phenotypic differences seen
in patient 5. A single large region of concordant homozygosity,
encompassing a genomic interval of ∼24 Mbp, was shared by
these four affected individuals (ﬁgure 1C).
To enrich the regions of interest prior to sequencing, we used
the SureSelect in-solution method (Agilent). Biotinylated oligo-
nucleotide baits were designed by extracting all coding regions
from the University of California, Santa Cruz (UCSC) genome
browser for the 993 unique RefSeq genes in the 24 Mbp Chr.6
locus, comprising a total target of 181 683 bp. These regions
were uploaded to Agilent’s ‘eArray’ software for automated
oligonucleotide synthesis (in parallel with regions for seven
other unrelated disease loci6). All subsequent steps, including
genomic DNA preparation, target enrichment, library prepar-
ation, sequencing on an Illumina GA-II, read alignment and
variant analysis, were performed as described.6 Mean depth of
coverage for targeted regions was 81, with 96% of target bases
covered by at least ﬁve reads of sufﬁcient base quality for
variant calling (Phred quality scores ≥17, mapping quality ≥20).
Exomes were enriched in solution with SureSelect XT
Human All Exon 50 Mb kits (V.3, Agilent). Sequencing was per-
formed as 100 bp paired-end runs on a HiSeq2000 system
(Illumina) generating 8–10 Gbp of sequence with an average
read depth of 100 and 92% of the target regions covered at
least 20 times. Sequence analysis was performed as described.7
Mutation veriﬁcation
Sanger sequencing of patients and other family members was
performed after PCR of genomic DNA derived from whole
blood. Sequencing was performed using BigDye Terminator
V.1.1 on an ABI 3730 (Applied Biosystems, Carlsbad,
California, USA). Primer sequences and PCR conditions are
available on request. Nucleotide numbering of HACE1 variants
is relative to reference sequence NM_020771.3.
Cell culture and immunoblotting
Primary dermal ﬁbroblasts of patients 6 and 7 (of family B)
were cultured in Dulbecco’s modiﬁed Eagle’s medium (PAA
Laboratories, Austria) supplemented with 10% foetal bovine
serum and 1% penicillin–streptomycin at 37°C in a saturated
humidiﬁed atmosphere containing 5% CO2. Cells were lysed in
an adequate volume of radioimmunoprecipitation assay (RIPA)
buffer. Protein concentration was determined using the colori-
metric Bradford assay, separated by sodium-dodecyl-sulfate-
polyacrylamide gel electrophoresis, and transferred to a polyvi-
nylidene ﬂuoride (PVDF) membrane (Roche, Mannheim).
HACE1 was visualised by the use of an anti-HACE1 antibody
(ab133637, Abcam) and an anti-GAPDH antibody (Cell
Signaling) was used as a loading control.
RESULTS
Clinical features
In family A, originating from the Mirpur region of
North-Eastern Pakistan and Kashmir (ﬁgure 1A), ﬁve individuals
had an undiagnosed neurodevelopmental disorder. The affected
subjects all had severe learning difﬁculties. Their parents all had
a normal phenotype.
In all affected individuals, hypotonia was noted either at birth
or by 3–4 months of age, and there were delayed early motor
milestones. All subsequently developed slowly progressive bilat-
eral lower limb spasticity. Lower limb power and function were
poor and most affected individuals were wheelchair users or
bed-bound, though two were mobile over short distances with
support. There was no evidence of wasting or fasciculation in
the lower limbs, and sensation was preserved. Epilepsy devel-
oped in all of the patients early in childhood. Language acquisi-
tion was conﬁned to a few single words and understanding was
limited. All were doubly incontinent.
Three of the four male subjects had hypoplastic genitalia
noted at birth. All four also had large heads from birth (91st–
99th centile). All had problems with weight gain and most were
signiﬁcantly overweight.
Patient 5 had additional problems. She developed presumed
viral encephalitis at age 1.5 years, requiring mechanical respira-
tory support for 6 days; this episode seemed to cause signiﬁcant
neurological regression. (Nonetheless, hypotonia and develop-
mental delay had been noted prior to this.) Her occipitofrontal
head circumference at birth had been on the 75th centile, but
was on the 2nd centile by age 3. She died aged 9 years second-
ary to a chest infection.
All ﬁve patients had ocular abnormalities: myopia, divergent
strabismus and/or retinal dystrophy. Sensorineural hearing loss
was diagnosed in three of the ﬁve patients.
Family B (ﬁgure 1B) was of German descent. A sister and two
dizygotic twin brothers all presented with a similar clinical syn-
drome comprising cognitive impairment, a hypotonic/ataxic
movement disorder resulting in an unsteady, broad-based gait
(see online supplementary video S1) and facial muscular hypo-
tonia with inarticulate speech. Patient 6 displayed developmental
delay. She was able to walk alone at the age of 4 years. Speech
development was severely delayed. She exhibits a lumbar lordo-
sis and a hypotonic-ataxic, intermittently dystonic movement
disorder. Patients 7 and 8 are the younger twin brothers of
patient 6. Patient 7 also presented developmental delay; inde-
pendent walking started at 3–4 years. Speech started at a normal
age but he has signiﬁcant articulation problems. He developed
epilepsy at the age of 2 years which is treated with antiepileptic
drugs. He manifests the hypotonic-ataxic movement disorder
most severely of the three siblings. His twin brother has the
mildest phenotype of the sibship. Independent walking was
achieved at 4½ years. In addition to a waddling gait, he shows
bilateral lower limb spasticity.
Genetic investigations for subtelomeric rearrangements, for
Prader–Willi and Rett syndromes and for myotonic dystrophies
types 1 and 2 proximal myotonic myopathy (PROMM) were all
normal.
The clinical features of the eight affected individuals are sum-
marised in table 1, while photographs are shown in online
supplementary ﬁgure S2.
Identiﬁcation of HACE1 as the causative gene
The complex consanguinity in family A allowed autozygosity
mapping, while in family B, the affected individuals were ana-
lysed by exome sequencing.
Patient 5 was set aside in the initial autozygosity mapping,
because of her phenotypic differences and consequent uncer-
tainty about whether she had the same disorder as patients 1–4.
The latter were found to share a single 24 Mbp concordant
autozygous region on Chr.6q (ﬁgure 1C). Patient 5 was geno-
typed in parallel, however, and noted to have a region of con-
cordant homozygosity within the same region of Chr.6q,
bounded by heterozygous SNPs rs2388039 and rs2016207
(chr6:97 747 244–109 982 160 on the hg19 build). Inclusion of
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Figure 1 (A) Simpliﬁed pedigree of family A. Affected individuals are shaded and numbered 1–5. The two deceased males with shaded symbols
were reported to have been affected with clinical features similar to those of patients 1–4. Asterisks indicate individuals used for autozygosity
mapping (C). Genotypes at position c.655 (reference sequence C, encoding arginine 219; mutant allele T) are shown. (B) Pedigree of family B.
(C) Autozygosity mapping using the ‘heterozygous SNPs’ view of AutoSNPa.5 Heterozygous SNPs (Affymetrix GeneChip Mapping 10K Array) appear
as black horizontal bars. Patients 1–4 have been assigned as affected, resulting in delineation of a 24 Mbp region of Chr.6 (pale blue shading) that
was concordantly homozygous. Patient 5 also has an interval devoid of heterozygous SNPs within the same region (blue bar); the genotypes are
again concordant in this subject (not shown). (D) Position of the truncating mutations within the domain structure of HACE1 and illustrative Sanger
sequence electropherograms of genomic PCR amplicons. In family B, the segregation of the compound heterozygous mutations is shown.
(E) Western blot analysis for HACE1 of cultured ﬁbroblasts from patients 6 and 7.
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Table 1 Clinical features of eight affected individuals from families A and B
Patient
Family A Family B
1 (male) 2 (male) 3 (male) 4 (male) 5 (female) 6 (female) 7 (male) 8 (male)
Gestation at birth
(weeks)
38 40 40 40 41 39 40 40
Birth weight (kg) 2.26 (2nd centile) 3.3 (25th centile) 3.85 (50th–75th centile) 3.74 (50th–75th centile) 4.05 (91st centile) 3.37 (mean) 3.4 (−0.9 SD) 3.2 (−1.5 SD)
Birth OFC (cm) 36.0 (91st–98th centile) 36.4 (75th–91st
centile)
38.2 (98th–99th centile) 38.4 (98th–99th centile) 35.4 (75th–91st centile) 33 (−1.2 SD) 34 (−1.8 SD) 34.5 (−1.1 SD)
Hypogenitalism Yes No Yes Yes No No No No
Lower limbs Bilateral spasticity Bilateral spasticity Bilateral spasticity Bilateral spasticity Bilateral spasticity – – Bilateral spasticity
Upper limbs Normal examination Dystonic posturing Normal examination Normal examination Increased tone and hyperreflexia Normal Dystonic
posturing
Normal
Epilepsy Myoclonic and tonic–clonic
epilepsy from 7 months
Myoclonic and
tonic–clonic
seizures from
5 years
None Tonic–clonic epilepsy
from 10 years
Myoclonic epilepsy from infancy None Myoclonic
seizures, focal
epilepsy
None
Recent growth parameters
Age 18 years 15 years 22 years 19 years 3 years 10 years
11 months
7 years 8 months 7 years 8 months
BMI (kg/m2) 33.3 37 55.7 50.4 20.6 24.8 21.17 19.32
OFC (cm) 59 (75th–91st centile) 59 (91st–98th
centile)
64 (>99th centile) 63 (>99th centile) 47.2 (<0.4th centile) 54 (+0.5 SD) 53 (+0.2 SD) 53 (+0.2 SD)
Mobility Never walked Never walked Age 16: mobile for short
distances with callipers
Age 15: 10–15 steps
with a rollator
Never walked Unstable,
waddling gait
Unstable,
waddling gait
Unstable, waddling
gait
Ophthalmic
findings
Divergent strabismus Divergent
strabismus
Right divergent strabismus,
bilateral myopia, right
macular hypoplasia, retinal
dystrophy
Divergent strabismus,
myopia, bilateral retinal
dystrophy
Severe myopia, left divergent
squint, sluggish pupil responses,
retinal dystrophy
Convergent
strabismus, bilateral
myopia, retinal
dystrophy
Hearing Bilateral sensorineural loss
(40 dB)
No abnormality Bilateral sensorineural loss
(30 dB)
No abnormality Bilateral sensorineural loss (40 dB) No abnormality No abnormality No abnormality
Neurological
investigations
CT scan: cerebral
underdevelopment and marked
atrophy of frontal and temporal
lobes.
EEG: consistent with myoclonic
epilepsy
No cranial imaging
performed
CT scan: generalised cerebral
atrophy
EEG: normal
CT scan: ventricular
dilatation
EEG: focal and generalised
spike-like discharges. Nerve
conduction studies normal.
MRI brain: prominent generalised
cerebral and brain stem atrophy,
disproportion between grey and
white matters.
ERG: Consistent with cone-rod
dystrophy
MRI:
hypoplastic
corpus callosum
EEG: normal
MRI: hypoplastic
corpus callosum
EEG: consistent
with myoclonic
epilepsy
MRI: enlarged
ventricles
EEG: normal
Skeletal Left talipes
equinovarus
Kyphosis
Erb’s palsy
Right subtalar fusion age
9 years
Calcaneovalgus
deformity of feet
Kyphoscoliosis
Bilateral hip dislocation
Pes planus Mild talipes
equinovarus
BMI, body mass index; ERG, electroretinography; OFC, occipitofrontal head circumference.
800
Hollstein
R,etal.J
M
ed
G
enet2015;52:797
–803.doi:10.1136/jm
edgenet-2015-103344
N
ew
loci
group.bmj.com
 o
n
 February 19, 2016 - Published by 
http://jmg.bmj.com/
D
ow
nloaded from
 
patient 5 and SNP 6.0 data obtained subsequently (see online
supplementary ﬁgure S1) would allow narrowing the common
concordant autozygous region to a 9.9 Mbp region between
rs158777 and rs6903501 (98 959 605–108 848 121).
We sequenced all the genes within the larger 24 Mbp autozy-
gous interval after enrichment by solution hybridisation, identi-
fying a total of 259 sequence variants. Of these, 44 remained
after ﬁltering out SNPs present in dbSNP129 with a minor
allele frequency (MAF) >0.01.
Only two of these variants were functional. A missense
change in MDN1 (NM_014611: c.4258A>G, p.M1420V) was
predicted to be tolerated. A homozygous nonsense mutation
c.655C>Twas identiﬁed within exon 8 of HACE1. Within the
predicted HACE1 protein structure, this mutation (p.R219*)
lies within the ﬁfth of the six N-terminal ankyrin repeats
(ﬁgure 1D); the truncated mutant protein is thus lacking the
entire catalytic HECT domain. Patients 1–5 were all homozy-
gous for this mutation.
In family B, DNA from the three affected individuals 6–8 was
subjected to exome sequencing. We used ∼6000 in-house
exomes from individuals with unrelated diseases to ﬁlter rare
variants (see online supplementary table S1). Using a MAF
threshold of 0.02, we detected only a single gene, HACE1, with
homozygous or compound heterozygous variants common to all
three siblings. In HACE1, we found the mutations c.2242C>T
and c.2019_2020insTTTAGGTATTTTTAGGTATT. The ﬁrst of
these predicts the protein truncating change p.R748* and was
shown by Sanger sequencing to be paternally derived. The 20 nt
insertion c.2019_2020insTTTAGGTATTTTTAGGTATT was
derived from the mother. The last 12 nt of this insertion are a
duplication of the reference genomic sequence immediately pre-
ceding the insertion point. If translated, this frameshifting muta-
tion predicts the almost immediate truncation of the protein p.
P674Ffs*5.
Homozygous or compound heterozygous occurrences of rare
non-synonymous HACE1 variants were only infrequently
observed in control individuals. Our in-house exomes contained
only one further exome carrying a homozygous HACE1 missense
variant, NM_020771.3:c.2659A>3, p.Ser887Arg. (This was in
an individual diagnosed with macrocephaly that was most likely
caused by a homozygous frameshift mutation in TBC1D7.) In
addition, only three rare (MAF<0.2) homozygous non-
synonymous missense variants (rs146393808, rs137941861,
rs34365906) and 21 putatively truncating, but heterozygous var-
iants were present in the ∼60 000 individuals queried through
the Exome Aggregation Consortium (ExAC) Browser. None of
the three mutations reported here was in ExAC (though R→Q
substitutions at both R219 and R748 are present).
The catalytic HECT domain of HACE1 is located at amino
acids 572–909, with its active cysteine residue at position 876
(see ref. 8, in which HACE1 is referred to as hectH20). All
three of the mutations described here, therefore, predict transla-
tion of a truncated HACE1 protein lacking part or all of the
catalytic domain. Deletion of the HACE1 HECT domain, or
mutation of the conserved HECT domain cysteine residue 876
(p.C876S), has previously been shown to cause loss of E3 ubi-
quitin ligase activity.9 10 The truncated proteins encoded by all
three mutant HACE1 alleles can therefore conﬁdently be
assumed to be devoid of catalytic activity.
We attempted to demonstrate the presence of truncated
protein in patient ﬁbroblasts from family B. While no
HACE1-speciﬁc signal was detected using a commercially avail-
able antibody against the N-terminal region of HACE1
(Origene), an antibody recognising the C-terminal HECT
domain (Abcam) yielded a speciﬁc band of the correct size
(∼102 kDa) in control ﬁbroblasts. As predicted, this band was
completely absent in cells from patients 6 and 7, conﬁrming
that mutant HACE1 is truncated and/or subject to nonsense-
mediated mRNA decay (ﬁgure 1E).
Given the normal phenotype of multiple carriers within
family A, and the absence of detectable HACE1 protein in ﬁbro-
blasts in family B, it is also highly likely that these mutant alleles
are null, rather than having any dominant negative function.
DISCUSSION
Here we report two families with eight affected children with
ID and other overlapping clinical features, including muscular
hypotonia, spasticity and ocular abnormalities. Autozygosity
mapping and whole exome sequencing revealed three
loss-of-function mutations in HACE1. In the consanguineous
family, a homozygous nonsense mutation p.R219* was identi-
ﬁed, while compound heterozygosity for another nonsense
mutation p.R748* and a 20 bp insertion were identiﬁed in the
German family. All three mutations are predicted to result in a
truncated protein lacking the entire (p.R219*) or most of the
catalytic HECT domain, and on that basis are assumed to be
loss-of-function mutations. Western blot analysis of patient cell
lines conﬁrmed the absence of the C-terminal immunoreactive
region; it remains possible that nonsense-mediated mRNA decay
contributes further to the lack of detectable HACE1.
The ﬁnding of individuals who are apparently null for
HACE1 function is unexpected, because HACE1 has previously
been postulated to be a tumour suppressor gene, inactivated in
Wilms’ tumour and other cancers.9 11 Support for this is
derived partly from loss of expression and/or epigenetic changes
in cancer cells; methylation changes resulting in reduced
HACE1 expression have also been associated with colon and
gastric cancer.12 13
However, in germline Hace1–/– knockout mice, a predispos-
ition for late-onset cancer and hypersensitivity to different car-
cinogenic factors was reported.11 In a child with bilateral,
early-onset Wilms’ tumour, Slade et al14 identiﬁed a t(5;6)(q21;
q21) translocation transecting HACE1. Among 421 additional
Wilms’ tumour patients, one was found to be heterozygous for a
truncating mutation (p.W364X), inherited from a healthy
parent. Both of these presumed loss-of-function mutations were
postulated to predispose to Wilms’ tumour.
While no truncating HACE1 variants are identiﬁable in
dbSNP and the 1000 genomes project, the current ExAC data-
base includes 21 putatively truncating variants among 60 706
exomes. Also, none of the patients or heterozygous mutation
carriers in either of our families was reported to have cancer.
Although we cannot at present exclude a predisposition for
late-onset tumours in the HACE1-deﬁcient individuals, it there-
fore appears possible that the previously reported heterozygous
mutations in cancer patients were incidental ﬁndings. Another
putative tumour suppressor gene recently shown to be mutated
in a neurodevelopmental syndrome is WWOX.15 16 Again, in
these studies patients homozygous for loss-of-function muta-
tions, as well as carriers, showed no cancer predisposition.
HACE1 (KIAA1320) is expressed in all regions of the brain
and at lower levels in other tissues.17 As an E3 ubiquitin ligase,
HACE1 recruits the E2 enzyme UBCH7 to ubiquitinate
HACE1-speciﬁc target proteins for subsequent degradation by
the 26S proteasome.9 One such target is the active form of
Rac1,18 a member of the Rho GTPase subfamily that is involved
in patterning cerebellar development by controlling cell mor-
phogenesis, migration and foliation.19 In mice, dysregulation of
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Rac1 causes neurodevelopmental phenotypes that may be rele-
vant to the human HACE1-deﬁciency phenotype; overexpres-
sion of constitutively active Rac120 and knockouts of Rac1
regulators21 result in perturbations of cerebellar development
manifesting with abnormal gait.
Rac1 is also involved in photoreceptor morphogenesis in
Drosophila and mice.22–24 In particular, constitutively active
Rac1 disrupts rod morphogenesis in mice, with defects in polar-
ity and migration. It is therefore possible that the retinal dys-
trophy and macular hypoplasia that are present in four of our
eight patients relate to a loss of Rac1 regulation by HACE1.
HACE1 also interacts with members of the Rab small GTPase
subfamily. Rab1 appears to recruit HACE1 to the Golgi, where
it plays a role in disassembly of the complex in mitosis.10
HACE1 is also reported to promote the recycling of the
β2-adrenergic receptor (β2-AR) through a Rab11a-dependent
mechanism.25
Besides its function as a E3 ubiquitin ligase, Zhao et al26
reported an E3-ligase independent interaction through which
HACE1 represses the transcriptional activity of retinoic acid
receptors RARα1, RARβ isoforms 1, 2 and 3; HACE1 thereby
also represses the RAR-regulated genes CRABPII, RIG1 and
RARβ2. The diverse regulatory roles of the RAR family imply
several possible downstream actions of HACE1; for example,
the CRABPII/RAR pathway mediates neuronal differentiation,27
while RARβ2 is involved in neuronal differentiation28 and
regeneration and stimulation of neurite outgrowth.29
In summary, we described here eight HACE1-deﬁcient indi-
viduals. Rather than the tumour predisposition phenotype that
might have been predicted from earlier literature, all have a
neurodevelopmental presentation. The patients show overlap-
ping clinical features such as ID, verbal dyspraxia, muscular
hypotonia, spasticity and ocular anomalies; however, the sever-
ity appears to be quite variable, particularly between family A
and family B. Further molecular study of HACE1 in neurode-
velopment, as well as identiﬁcation of other HACE1-deﬁcient
subjects, should permit a better understanding of the physio-
logical function of this gene and its genotype–phenotype
relationships.
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